Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Melanoma 7Prostatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Recurrence 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lung Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

toripalimab 2Trabectedin 2Doxorubicin 2Docetaxel 2Biopsy 2temsirolimus 1silmitasertib 1selinexor 1pazopanib 1palbociclib 1nilotinib 1mirdametinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Vincristine 1Temozolomide 1Specimen Handling 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Proton Therapy 1Nelfinavir 1Irinotecan 1Immunoenzyme Techniques 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × cemiplimab × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡